HER2 positive means the cancer makes too much of a protein called HER2, which pushes it to grow and spread faster. It used to be worrying news, but it now opens the door to targeted drugs like trastuzumab that lock onto HER2 and work alongside chemotherapy and surgery. So while these cancers are more aggressive by nature, they’re also among the most treatable today thanks to that targeted approach.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “Twenty years ago HER2 positive was bad news, today it’s almost the opposite, because we have drugs that target it directly, so I treat that result as an opportunity, not a setback.”

The result points to how the cancer behaves and, more importantly, how to fight it. Here’s what it signals.

• Extra HER2 protein: The cancer cells carry far too much of this growth signal, which is what drives them to multiply more quickly than usual.
• More aggressive type: Left untreated it tends to grow and spread faster, so it’s taken seriously and treated promptly once confirmed.
• A clear target: That same protein is its weak spot, since targeted drugs can lock onto HER2 in a way that spares healthy cells.
• Confirmed by testing: The status comes from lab testing on the tumour, and a borderline result is double-checked before treatment is set.

So the label tells you both the threat and the route to beat it. The status itself comes from an IHC test, which reads exactly this kind of marker on the tumour.

A positive result reshapes the plan in a good way, adding tools that wouldn’t otherwise apply. These are the main shifts.

• Targeted therapy added: Drugs like trastuzumab go straight after the HER2 protein, and they’ve transformed outcomes for these cancers.
• Chemo works with it: Targeted therapy usually pairs with chemotherapy, the two together hitting the cancer harder than either alone.
• Surgery still matters: Removing the tumour stays central, with the targeted drugs working before or after to clear what’s left.
• Closer monitoring: Because these cancers move faster, follow-up tends to be tighter to catch any change early.

So HER2 positive today means more weapons, not fewer. When surgery is part of that plan, robotic cancer surgery can remove the tumour precisely while recovery stays short.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery to the treatment of HER2 positive and all other cancer types. He builds the surgery around the full molecular picture, so a marker like HER2 shapes the plan from the very start rather than later.

That joined-up approach is what gives targeted treatment its best footing. Every case at MACS Clinic goes through a full tumour board, where pathology, oncology and imaging weigh in together before anything is confirmed. Call +91 8104310753 to book your consultation.

References:

1. National Cancer Institute — HER2 and Cancer. https://www.cancer.gov/
2. World Health Organisation — Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer

Start with a few key parts and the report stops looking like a wall of jargon. The diagnosis line tells you whether the tissue is benign or malignant. The type and grade describe what the cancer is and how aggressive it looks. Margin status says whether it was fully removed. These sections carry the real meaning, though your doctor should always be the one to interpret them for your case.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “Patients should understand their own report, but I always warn them that one scary word out of context can cause needless panic, so read it to ask better questions, not to self-diagnose.”

A biopsy report follows a pattern once you know where to look. These are the sections that matter most.

• The diagnosis: This is the headline, telling you plainly whether the tissue is benign, malignant or needs more testing before anyone’s sure.
• Type and grade: Type names the cancer, while grade rates how abnormal the cells look, which hints at how fast it might grow.
• Margins: When tissue is removed, this says whether cancer reaches the cut edge, and a clear margin is exactly what you want to see.
• Extra markers: Hormone receptors, HER2 or similar findings appear here, and they often steer what treatment comes next.

So the report is really a few key answers wrapped in technical language. For the bigger picture of where it comes from, our blog on a biopsy explains the process behind it.

A handful of words trip people up and spark worry they don’t need to. Here’s what they actually mean.

• “Atypical”: It sounds alarming but often isn’t cancer, just cells that look unusual and may need a closer second look.
• “In situ”: This means the cancer is still contained where it started and hasn’t spread, which is generally an early, favourable finding.
• “Poorly differentiated”: It describes cells that look very abnormal, which can mean faster growth, but it’s only one piece of the full picture.
• “Positive margin”: This flags cancer at the edge of removed tissue, sometimes meaning a bit more surgery, not that anything has gone wrong.

So a frightening term rarely tells the whole story on its own. For tailored options, robotic cancer surgery is one path a clear report can point toward.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery to reading and acting on biopsy reports across all cancer types. He walks patients through their report line by line, turning intimidating terminology into something they can actually understand.

That plain explanation is what replaces fear with a clear next step. Every case at MACS Clinic goes through a full tumour board, where pathology, imaging and oncology weigh in together before anything is confirmed. Call +91 8104310753 to book your consultation.

References:

1. National Cancer Institute — Understanding Your Pathology Report. https://www.cancer.gov/
2. World Health Organisation — Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer

Not for everyone, but for certain cancers it genuinely matters. Genetic testing looks for inherited gene changes, like BRCA in breast and ovarian cancer, that can change how much tissue a surgeon should remove and whether the other side needs attention too. For most cancers it isn’t required, yet where a known gene is involved, the result can reshape the whole surgical plan. That’s why it’s considered case by case.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “When a patient carries a gene like BRCA, I plan the surgery differently, sometimes far more extensively, so I’d rather know before I operate than discover it afterwards.”

It isn’t routine for every patient, but in some situations it really earns its place. Here’s when.

• A strong family history: Several close relatives with the same cancer is a red flag that an inherited gene may be in play, and that’s worth checking first.
• Young at diagnosis: Cancer showing up unusually early often points to a genetic cause, which can change how the surgery is approached.
• Specific cancers: Breast, ovarian and colorectal cancers have well-known gene links, so testing here can directly affect the operation chosen.
• It changes the plan: If a result would mean removing more tissue or operating on both sides, knowing beforehand beats finding out later.

So testing first is about operating with the full picture. Much like what an IHC test adds at the cell level, a gene result fills in detail the surgeon needs before deciding.

When a gene shows up, it can shift the plan in real, practical ways. These are the main ones.

• Wider removal: A BRCA result in breast cancer, for instance, may steer a patient toward removing more tissue rather than a smaller operation.
• Both sides considered: Some inherited risks raise the odds for the other breast or ovary, so surgery may be planned to cover both.
• Timing other organs: A strong gene result sometimes brings forward preventive surgery on organs not yet affected.
• Family gets warning: A positive result flags risk for close relatives too, letting them screen early long before anything shows.

So the gene doesn’t just inform your surgery, it can protect your family. For suitable cases, robotic cancer surgery then carries out that tailored plan with precision.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery to surgery across all cancer types. He factors genetic results into the surgical plan from the start, rather than treating them as an afterthought once the operation is already decided.

That forward planning is what makes a surgery fit the patient, not just the tumour. Every case at MACS Clinic goes through a full tumour board, where genetics, pathology and imaging are weighed together before anything is confirmed. Call +91 8104310753 to book your consultation.

References:

1. National Cancer Institute — Genetic Testing for Cancer. https://www.cancer.gov/
2. World Health Organisation — Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer

Whether chemotherapy comes first (neoadjuvant) or surgery comes first (adjuvant) depends entirely on the tumour size, cancer type and stage. A multidisciplinary tumour board makes this call, weighing how best to achieve a complete cure, shrink the tumour to allow less invasive surgery, or lower the risk of the cancer coming back. So the order is picked to fit your case, not by some fixed rule.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “I’d never decide the order alone or out of habit, because for some cancers chemo first changes what surgery can actually achieve, and getting that sequence right matters as much as the operation itself.”

Sometimes it makes more sense to treat the body before touching the tumour. Here’s when.

• To shrink it down: A big or awkwardly placed tumour often softens up with chemo first, which makes it smaller and a lot easier to take out cleanly.
• To catch hidden spread: If there’s a real chance stray cells have slipped out, chemo upfront goes after them before surgery handles the main lump.
• To see how it responds: Chemo first shows how the tumour reacts to the drugs, and that tells the team what to do after the operation.
• Certain cancers: Breast, rectal and some stomach cancers just do better with chemo leading, because that’s what the evidence keeps showing.

So chemo first isn’t a delay, it’s a plan. Working out the right order for your case is exactly why a second opinion before treatment is worth it.

Other times you just take the tumour out and get on with it. These are those cases.

• It’s clearly removable: When the tumour is contained and operable as it stands, there’s no real reason to wait, so surgery goes first.
• You need the full pathology: Removing it first gives the complete read on type and grade, and that shapes whatever chemo follows.
• Chemo won’t help yet: Some cancers simply don’t shrink with chemo, so holding back surgery for it would gain nothing.
• It can’t wait: A tumour blocking, bleeding or pressing on something usually has to come out first, whatever the long game looks like.

So surgery first is about acting when waiting buys you nothing. In the right cases, robotic cancer surgery takes the tumour out precisely and gets recovery moving sooner.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery to every treatment decision across all cancer types. He weighs the order of treatment on the evidence and your specific case, rather than defaulting to whichever step is quickest.

That careful sequencing is what gives a treatment plan its best chance. Every case at MACS Clinic goes through a full tumour board, where surgery, chemotherapy and radiation are weighed together before the order is set. Call +91 8104310753 to book your consultation.

References:

1. National Cancer Institute — Types of Cancer Treatment. https://www.cancer.gov/
2. World Health Organisation — Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer

Stage 2 cancer is both treatable and, in most cases, curable. The tumour has grown a little or reached nearby lymph nodes, but it hasn’t spread to distant organs, and that’s what keeps the chance of a full cure high. Treatment usually means surgery, sometimes with chemo or radiation added. How it plays out still depends on the exact cancer.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “Stage 2 is where I’m genuinely aiming for a cure in most cases, not just control, but the word covers very different cancers, so the number alone never tells the whole story for a patient.”

The number tells you how far things have gone, not how bad they have to turn out.

• It’s grown a bit: Bigger than stage 1, or into nearby tissue, but still sitting in or around where it first started.
• A few nodes, maybe: Some close lymph nodes can be involved. That’s not the same thing as the cancer reaching distant organs.
• Nothing far off: The key point is that it hasn’t travelled across the body, and that’s what keeps a cure well within reach.
• Depends on the cancer: Stage 2 in the breast and stage 2 in the stomach are different battles, so the label shifts meaning by site.

So stage 2 sits squarely in treatable, often curable, territory. Pinning down exactly where you stand is why a second opinion here is worth the time.

The aim is to cure it, and surgery normally leads the way.

• Surgery up front: For most solid stage 2 cancers, taking the tumour out is the main move, and often it’s all that’s needed.
• Chemo if needed: Some people have chemo afterwards to mop up stray cells and cut the odds of it returning.
• Radiation sometimes: In breast or rectal cancers especially, targeted radiation may follow to cover the area properly.
• The board decides: What gets combined is worked out case by case, going on cancer type, your health and what the scans show.

So the whole plan is built to beat it, not just keep it in check. In suitable cases, robotic cancer surgery takes the tumour out precisely and gets people home sooner.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery to the treatment of every stage and type of cancer. He explains plainly what a stage 2 diagnosis means for the chance of cure, rather than leaving patients to fear the number alone.

That honest framing is what turns a frightening label into a clear plan. Every case at MACS Clinic goes through a full tumour board, where pathology, imaging and oncology weigh in together before anything is confirmed. Call +91 8104310753 to book your consultation.

References:

1. National Cancer Institute — Cancer Staging. https://www.cancer.gov/
2. World Health Organisation — Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer